Clinical History
An 86-year-old male was admitted via ambulance presenting with an episode of severe dizziness and impending syncope. His cardiac history included:
- 2004: Initial implantation of a dual-chamber pacemaker (DDDR) due to atrioventricular block.
- 2020: Generator replacement, subsequent explantation due to device-related infection, and contralateral re-implantation of a new DDDR system.
- Pacemaker dependency: The patient was fully dependent on atrial and ventricular pacing.
Diagnostic Approach & Clinical Presentation
Upon admission, sustained monomorphic ventricular tachycardia (VT) was documented, exhibiting a right bundle branch block (RBBB) morphology with an inferior axis. The patient was transferred to the Intensive Care Unit (ICU) due to hemodynamic instability resulting from recurrent episodes of VT.
- Pharmacological management: The arrhythmia was successfully suppressed to brief episodes of non-sustained ventricular tachycardia (NSVT) following the combined administration of amiodarone and mexiletine.
- Echocardiography: Demonstrated dilated cardiomyopathy with severe left ventricular systolic dysfunction (Ejection Fraction 10-15%).
- Coronary angiography: Performed to rule out an ischemic etiology; it revealed no significant coronary artery stenoses.
Interventional Management & Complication Handling
The primary objective was to upgrade the system to a biventricular defibrillator (CRT-D). During the procedure, however, venography revealed a complete occlusion of the superior vena cava (SVC), with extensive collateral circulation developing through the azygous vein (Video 1).
Considering the patient’s advanced age and the high risk associated with a potential explantation of the chronic leads, lead extraction was not attempted. Furthermore, the paced QRS duration from the existing lead (positioned at the interventricular septum) was already 130 ms, rendering biventricular support non-imperative.
Consequently, implantation of an implantable cardioverter-defibrillator (ICD) with a single-coil lead positioned in the azygous vein was pursued. Notably, due to the pre-existing anatomical communication between the azygous vein and the superior vena cava, the azygous vein functioned as the primary collateral pathway following SVC occlusion (Videos 1-2). Furthermore, due to its stable posterior cardiac course, the azygous vein provided an optimal vector for ensuring effective defibrillation (shock vector). Pacing and sensing functions were assigned to the pre-existing, already established leads (Fig. 1-3).
- Access: A left subclavian vein puncture was performed. Utilizing a long peel-away sheath, the defibrillation lead was advanced and stabilized within the azygous vein, directly posterior to the cardiac silhouette.
- Parameter Evaluation:
- Atrium (chronic lead): P-wave: 1 mV, impedance: 480 Ω, threshold: 1 V / 0.5 ms.
- Right Ventricle (chronic lead): impedance: 460 Ω, threshold: 1 V / 0.5 ms.
- Defibrillation Impedance (Shocking Impedance): 74 Ω.
- Defibrillation Threshold Testing: The Upper Limit of Vulnerability (ULV) method was employed. By delivering a 24 J shock on the T-wave (shock on T), ventricular fibrillation was not induced, thereby confirming a satisfactory safety margin for the system.
Postoperative Course
The procedure was completed without complications. The patient remained hospitalized for the optimization of medical therapy for heart failure. The ventricular tachycardia was fully controlled via the systematic administration of antiarrhythmic medications (amiodarone, mexiletine). The patient was discharged in a stable clinical condition.
Discussion
Central venous occlusion represents a well-documented, long-term complication in patients with a history of multiple or chronic pacemaker leads. In this specific case, the complete occlusion of the superior vena cava was compensated for by the pre-existing anatomical communication with the azygous vein, which served as the primary collateral venous pathway. Although lead explantation is the conventional method to clear an access route, the patient’s advanced age and severe heart failure rendered such an intervention exceptionally high-risk.
The selection of the azygous vein as an alternative pathway was based exclusively on its distinct anatomical characteristics. Given that the azygous vein follows a stable retrocardiac course in the posterior mediastinum, positioning the defibrillation lead (coil) at this site—in combination with the left pectoral position of the generator (can)—created an ideal defibrillation vector (shock vector). The electrical field generated during discharge successfully encompasses and penetrates the left ventricular mass from the posterior to the anterior surface. This approach facilitated the successful upgrade of the system to a defibrillator with an exceptionally safe defibrillation threshold, completely avoiding the potentially fatal complications of lead explantation.
Although contemporary guidelines omit routine defibrillation threshold (DFT) testing in standard implantations, testing was mandatory in this case due to the non-conventional, extracardiac position of the lead. To confirm system efficacy without inducing fibrillation, the Upper Limit of Vulnerability (ULV) method was selected. The application of a 24 J shock on the T-wave failed to induce arrhythmia, indirectly documenting a lower true defibrillation threshold. This successful test confirmed that the retrocardiac vector achieved via the azygous vein ensures an excellent safety margin for terminating future arrhythmic events.

Fig. 1

Fig 2.

Fig 3.